

## Special Issue

# New Insights into Breast Cancer Management: From Tumorigenesis to Personalized Treatments

### Message from the Guest Editors

Breast cancer is a heterogeneous disease with multifactorial etiopathogenesis. Over the last few decades, a deeper understanding of the molecular mechanisms underlying breast cancer development and progression has led to the development of novel accurate prognostic analyses and new effective drugs, thus leading to an increase in the overall survival of breast cancer patients. Nevertheless, breast cancer remains the second leading cause of death in women globally. Thus, there is still a need for a better comprehension of the complexity of breast cancer and the interaction between the neoplasm and its microenvironment as well as the immune system in order to prevent disease development and to guide personalized treatments. Moreover, since individual response to therapy and long-term prognosis remain highly unpredictable, the current scenario requires the identification of biomarkers that accurately forecast the response to therapy and identify patients who will not benefit from standard regimens. On the other hand, since the number of breast cancer survivors is continuously increasing, knowing the complexity of breast cancer survivorship is essential for adequate patient management.

### Guest Editors

Dr. Paola Tiberio

Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy

Dr. Rita De Sanctis

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy

### Deadline for manuscript submissions

closed (31 May 2025)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/177044](https://mdpi.com/si/177044)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).